Psychedelic Medicine

Association

Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation

Excerpts from the publication

Recent studies have demonstrated the promise of psilocybin therapies in creating positive changes for those with poor mental health across multiple diagnostic categories, including major depressive disorder (MDD), end-of-life anxiety, and obsessive-compulsive disorder (OCD). While there may be a large population that is eligible to participate in psilocybin therapy based on psychiatric diagnosis and medical clearance, little attention has been given to intrapersonal and interpersonal factors that might influence patient’s readiness (i.e., eligibility and capacity) for psychedelic interventions. This paper proposes that readiness assessment includes both intrapersonal and interpersonal factors in order to improve safety, patient care, and treatment outcomes. While at the present time a reliable and valid instrument has not been developed, we propose that three specific areas of focus – patient presentation, therapeutic alliance, and patient safety – may be used to establish a patient’s readiness for psilocybin therapy, thus increasing therapy optimization and personalization.

Read more

Psychedelics and Eating Disorders: Exploring the Therapeutic Potential for Anorexia Nervosa and Beyond

Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial

A non-hallucinogenic LSD analog with therapeutic potential for mood disorders

Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up

Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments

Expectancy in placebo-controlled trials of psychedelics: if so, so what?